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Abstract
Background: Metastasis to the pituitary gland is extremely rare and is often detected incidentally by symptoms
associated with endocrine dysfunction. Breast and lung cancer are the most common primary metastasizing to pituitary
gland. Metastasis from hepatocellular carcinoma to the pituitary gland is extremely rare, with only 10 cases having been
previously reported. We present here the first case of pituitary metastasis of hepatocellular carcinoma presenting with
panhypopituitarism diagnosed by magnetic resonance imaging.
Case presentation: We report the case of an 80-year-old Japanese woman who presented with the sudden onset of
hypotension and bradycardia after having previously been diagnosed with hepatocellular carcinoma. Based on low levels
of pituitary hormones, she was diagnosed with panhypopituitarism caused by metastasis of the hepatocellular carcinoma
to the pituitary gland. Magnetic resonance imaging with arterial spin-labeling was effective in the differential diagnosis of
the intrasellar tumor. The patient died despite hormone replacement therapy because of hypovolemic shock.
Conclusion: Metastasis to the pituitary gland causes various non-specific symptoms, so it is difficult to diagnose. The
present case emphasizes the importance of diagnostic imaging in identifying these metastases. Clinicians should consider
the possibility of pituitary metastasis in patients with malignant tumors who demonstrate hypopituitarism.
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Background
Intracranial metastasis to the pituitary gland is rare. The
reported incidence of pituitary metastasis is 0.87 % and
1.9 % of all intracranial metastases and autopsied cancer
patients, respectively. Breast and lung cancer are the most
common primary carcinomas causing pituitary metastasis
[1]. Metastasis from hepatocellular carcinoma (HCC) to
the pituitary gland is extremely rare, with only 10 cases
having been previously described [1–9]. Here, we report a
case of pituitary metastasis from HCC in which the patient
presented with hypotension and bradycardia. In addition,
we highlight the use of magnetic resonance imaging (MRI)
for the differential diagnosis of the intrasellar tumor.
Case presentation
In November 2011, an 80-year-old woman exhibited
sudden-onset anorexia accompanied by hypotension and
bradycardia. She had previously been treated for hepatitis
C virus-related cirrhosis and HCC in August 2002. The pa-
tient suffered multiple relapses of HCC and had undergone
four radiofrequency ablation cycles and two transcatheter
arterial chemoembolization cycles. Routine laboratory tests
detected a mild elevation of serum aspartate aminotrans-
ferase to 81 IU/L (normal level, <34 IU/L). An additional
endocrinological work-up detected thyroid hormone, corti-
sol, and adrenocorticotropic hormone insufficiencies, with
normal levels of thyroid stimulation hormone (Table 1).
These results were indicative of hypopituitarism.
MRI of the brain revealed a tumor measuring 13 mm ×
13 mm in the sella turcica, which had spread across the
suprasellar region (Fig. 1a) and was likely the cause of
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the panhypopituitarism. Magnetic resonance perfusion
with arterial spin-labeling (ASL) indicated that the tumor
had hyperperfusion nature (Fig. 1b). This finding was com-
patible with pituitary metastasis, with HCC as the primary
lesion. Subsequent computed tomography (CT) scans of
the thorax, abdomen, and pelvis identified no other primary
lesions. Finally, a clinical diagnosis of HCC metastasis to
the pituitary gland causing panhypopituitarism was made.
Steroid and thyroid hormone replacement therapy was
used to treat the patient’s panhypopituitarism, resulting
in stabilization of her blood pressure and pulse. How-
ever, diabetes insipidus (DI) developed five days into the
replacement therapy, and the patient’s daily output of
urine was more than 2.5 L. Urine output decreased only
temporarily following treatment with desmopressin, but
increased to 6.0 L/day one week into treatment. Two
weeks after the initial diagnosis of pituitary metastasis,
MRI revealed enlargement and subsequent hemorrha-
ging of the metastatic pituitary tumor.
Table 1 Basal endocrine evaluation
Hormone Level measured Normal levels
GH 0.360 ng/mL 0.010–3.607 ng/mL
PRL 6.83 ng/mL <12.3 ng/mL
TSH 1.288 μIU/mL 0.350–4.940 μIU/mL
FT3 1.78 pg/mL 1.71–3.71 pg/mL
FT4 <0.40 ng/dL 0.70–1.48 ng/dL
ACTH 1.4 pg/mL 7.2–63.3 pg/mL
Cortisol 3.1 μg/dL 4.0–19.3 μg/dL
Aldosterone 10 pg/mL 36–240 pg/mL
Plasma renin activity 0.5 ng/mL 0.2–3.9 ng/mL
ADH 0.27 pg/mL 0.3–4.2 pg/mL
LH <0.10 mIU/mL 7.5–56.2 mIU/mL
FSH 0.27 mIU/mL 9.2–124.7 mIU/mL
Bold text indicates abnormal data
GH: growth hormone, PRL: prolactin, TSH: thyroid-stimulating hormone, FT3: free
triiodothyronine, FT4: free thyroxine, ACTH: adrenocorticotropic hormone, ADH:
antidiuretic hormone, LH: luteinizing hormone, FSH: follicle-stimulating hormone
Fig. 1 Magnetic resonance images of the patient on admission. (a) Axial T2-weighted image showing a tumor located in supra-sellar region (arrow). The
tumor is imaged as same intensity as gray matter. (b) Arterial spin labeling (ASL) perfusion weighted image corresponding to the section of (a). The tumor
is revealed as bright hyper-intensity mass (arrow), suggesting elevated blood flow. (c) Sagittal T1-weighted pre-contrast image. The tumor is located in
pituitary fossa and had spread across the suprasellar region (arrows). (d) ASL fusion image onto a T2-weighted image. The fusion image demonstrates
high blood flow signal exactly corresponds to the tumor mass (arrows).
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In January 2012, the patient died of hypovolemic shock.
Postmortem examination of the pituitary tumor revealed
tumoral hepatocytes in a thick trabecular pattern, the typ-
ical appearance of well differentiated HCC (Fig. 2a). The
tumor was immunopositive for hepatocytes, α-fetoprotein,
and glypican-3 (Fig. 2, b-d). These findings were compatible
with a diagnosis of HCC metastasis to the pituitary gland.
Discussion
As noted above, metastasis to the pituitary gland is ex-
tremely rare. The incidence of pituitary metastasis is less
than 1 % among all patients with intracranial metastases
[1]. A review of the literature revealed that breast and
lung cancers are the most common primary tumors to
metastasize to the pituitary gland. The prognosis of pitu-
itary metastasis is poor and is related to the histological
subtype and stage of the primary malignancy rather than
to the presence of the metastasis itself [1].
The differential diagnosis of intrasellar tumors requires
the exclusion of such diseases as hypophyseal adenoma, cra-
niopharyngioma, meningioma, Rathke’s cleft cyst, and
aneurysm. Fassett et al. reported that differentiation of a pi-
tuitary metastasis from other pituitary tumors based on neu-
roimaging alone can be difficult, although certain features,
such as thickening of the pituitary stalk, invasion of the cav-
ernous sinus, and sclerosis of the surrounding sella turcica,
can indicate metastasis [10]. On the other hand, Post points
out in his recent commentary that imaging techniques, such
as MRI or CT, can distinguish metastatic disease if the pitu-
itary gland is visually separate from the tumor or if excessive
bone destruction is evident [11]. In the current case,
although we did not observe these specific features of meta-
static disease, magnetic resonance perfusion with ASL
allowed us to differentially diagnose the pituitary metastasis.
ASL is a unique perfusion imaging method, especially
for the brain, that can generate images without injection
of contrast material. Its clinical utility has been estab-
lished in several cerebral conditions such as brain
tumors, infarction, and vascular lesions [12–14]. In our
case, ASL clearly showed hyper-perfusion nature of the
tumor, indicative of a metastatic tumor rather than pitu-
itary macro adenoma, which is more frequent but rarely
exhibit such blood flow, though other supra-sellar
tumors such as meningioma or craniopharyngioma may
also be revealed as hyperperfusion on ASL image.
The patient exhibited a sudden onset of hypotension
with bradycardia, symptoms which were suspected to be
the result of panhypopituitarism. This was later confirmed
by a blood test. On the other hand, the most common
symptom of pituitary metastasis is DI [6–8, 15], because
the posterior lobe receives direct blood flow from systemic
circulation [9, 15]. However, Peppa et al. described that
the symptoms of metastasis to the pituitary gland are not
specific and include fatigue, weight loss, dizziness, nausea,
and vomiting. Therefore, symptoms of pituitary metastasis
are often mistaken for those of cancer cachexia [16].
These data suggest that metastasis to the pituitary gland
should be suspected when a patient with advanced malig-
nancy shows unaccountable, non-specific symptoms.
Distinguishing metastasis to the pituitary gland from
metastasis to the skull base (sphenoid sinus, cavernous
sinus, and sella turcica) is very difficult because of the
Fig. 2 Histological tumor specimens (magnification × 400). (a) Hematoxylin and eosin staining of the pituitary tumor demonstrating a tumor with
cord-like structure. Immunohistochemical expression of (b) hepatocytes, (c) glypican-3, and (d) α-fetoprotein.
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close proximity of these regions [15]. To establish a
diagnosis, pathological confirmation is required. In gen-
eral, bone metastasis from HCC is estimated to occur in
2-16 % of all HCC patients and may often spread to the
vertebrae, ribs, pelvis, and long bones [17]. In the
current case, metastasis of HCC to the skull base could
not be excluded during the patient’s lifetime, but metas-
tasis to the pituitary gland was definitively diagnosed by
histological findings in the postmortem examination.
For the treatment of metastatic pituitary tumors, Morita
et al. reported that there were no significant differences in
survival times between surgical and nonsurgical treat-
ments [9]. The vascularity of metastatic tumors is ex-
tremely rich; therefore, surgery is sometimes performed
not only for palliation, but also for prevention of
hemorrhage [15]. Additionally, surgery improves the qual-
ity of life and provides pathologic confirmation of the dis-
ease [11]. Before surgery and biopsy, it is advantageous for
ASL image to obtain how much of vasculature the tumor
has and to assess the risk of bleeding at the surgical treat-
ment. In the current case, surgery was not performed
because the patient was in the terminal stage of advanced
HCC. However, if the growth of HCC is well controlled,
surgery is an attractive choice.
Conclusions
We reported a case of HCC metastasis to the pituitary
gland presenting with panhypopituitarism. The present
case emphasizes the importance of diagnostic imaging in
identifying these metastases. Metastasis to the pituitary
gland causes various non-specific symptoms. It is
important to consider a metastasis to the pituitary gland
when an HCC patient exhibits nonspecific symptoms
associated with panhypopituitarism.
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